Hostname: page-component-77c89778f8-9q27g Total loading time: 0 Render date: 2024-07-20T19:31:19.488Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Management of Major Depressive Disorder

Published online by Cambridge University Press:  07 November 2014

Laurence Mignon  and
Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Extract

The World Health Organization estimates that depression is the fourth leading cause of disability worldwide with a lifetime prevalence of ∼15% to 20%. While the antidepressants currently on the market will be effective in most patients, a significant number of patients will experience residual symptoms, treatment-resistance, and relapse. The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study has shed some light on the reality of antidepressant treatment. At first, only one-third of patients on citalopram monotherapy remitted. The other two-thirds who failed to remit saw their likelihood of remission decrease with each successive trial of another antidepressant monotherapy. Thus, after four successive monotherapies were tried over the course of one year, (ie, after four treatments each lasting 12 weeks), only two-thirds of patients achieved remission (Figure 1). Besides this poor prognosis, the patients who required more treatment cycles to get better also had a higher likelihood of relapsing. Once patients reach that point, they are considered treatment-resistant.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S10 , November 2009 , pp. 3 - 6
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Rubinow, DR. Treatment strategies after SSRI failure--good news and bad news. N Eng J Med. 2006;354(12):1305–1307.CrossRefGoogle ScholarPubMed
2.Warden, D, Rush, AJ, Trivedi, MH, Fava, M, Wisniewski, SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459.CrossRefGoogle ScholarPubMed
3.Stahl, SM. Stahl's Essential Psychopharmacology. 3rd ed.New York, NY: Cambridge University Press; 2008.Google Scholar
4.Rapaport, MH. Beyond acute treatment of depressive disorders. J Clin Psychiatry. 2009;70(7):e21.CrossRefGoogle ScholarPubMed
5.Pompili, M, Serafini, G, Del Casale, A et al. , Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Exeprt Rev Neurother. 2009;9(7):985–1004.CrossRefGoogle ScholarPubMed
6.Nierenberg, AA, Husain, MM, Trivedi, MH et al. , Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2009:1–10.Google ScholarPubMed
7.Berk, M. Sleep and depression - theory and practice. Aust Fam Physician. 2009;38(5):302–304.Google ScholarPubMed
8.Fava, M, McCall, WV, Krystal, A et al. , Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052–1060.CrossRefGoogle ScholarPubMed
9.Stahl, SM. Combining antidepressant therapies form the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry. In press.Google Scholar
10.Kurian, BT, Greer, TL, Trivedi, MH. Strategies to enhance the therapeutic efficacy of antide-pressants: targeting residual symptoms. Expert Rev Neurother. 2009;9(7):975–984.CrossRefGoogle Scholar
11.Clark, L, Chamberlain, SR, Sahakian, BJ. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci. 2009;32:57–74.CrossRefGoogle ScholarPubMed
12.Kaplan, KA, Harvey, AG. Hypersomnia across mood disorders: a review and synthesis. Sleep Med Rev. 2009;13(4):275–285.CrossRefGoogle ScholarPubMed
13.Baldwin, DS, Papakostas, GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006;67(suppl 6):9–15.Google ScholarPubMed
14.Kroenke, K, Krebs, EE, Bair, MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206–219.CrossRefGoogle ScholarPubMed
15.Shansky, RM. Estrogen, stress and the brain: progress toward unraveling gender discrepancies in major depressive disorder. Expert Rev Neurother. 2009;9(7):967–973.CrossRefGoogle ScholarPubMed
16.Zender, R, Olshansky, E. Women's mental health: depression and anxiety. Nurs Clin North Am. 2009;44(3):355–364.CrossRefGoogle ScholarPubMed
17.Stahl, SM. Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry. 2009;70(1):11–12.CrossRefGoogle ScholarPubMed
18.Stahl, SM. Vasomotor symptoms and depression in women, part 2. Treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasomotor symptoms. J Clin Psychiatry. 2009;70(3):310–311.CrossRefGoogle ScholarPubMed
19.Laurent, SM, Simons, AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev. 2009;29(7):573–585.CrossRefGoogle ScholarPubMed
20.Koreman, SG. Epidemiology of erectile dysfunction. Endocrine. 2004;23(2–3):87–91.CrossRefGoogle Scholar
21.Conway, KP, Compton, W, Stinson, FS, Grant, BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247–257.CrossRefGoogle ScholarPubMed
22.Prager, LM. Depression and suicide in children and adolescents. Pediatr Rev. 2009;30(6):199–205.CrossRefGoogle ScholarPubMed
23.Blier, P, Gobbi, G, Turcotte, JE et al. , Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457–465.CrossRefGoogle ScholarPubMed